This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: PAH

January 2009 Br J Cardiol 2009;16(Suppl 1):S4-S6

What scientific progress have we made in PAH?

BJCardio editorial team

Abstract

Since then, there has been a steady exploration of the molecular mechanisms underlying PAH, which has led to development of effective targeted therapeutic options such as endothelin receptor antagonists and prostacyclin derivatives. In Professor Rubin’s view, these options represent a major success, but he hoped that there would be further progress. Many patients may not respond to these therapies, and it remains a serious and life-threatening disease. The characterisation of PAH into its clinical, pathobiological and epidemiological components has provided the opportunity to intervene therapeutically and to delay disease progression. Three

| Full text

January 2009 Br J Cardiol 2009;16(Suppl 1):S13-S14

Future of PAH: what does success look like?

BJCardio editorial team

Abstract

Table 1: Emerging issues in pulmonary arterial hypertension (PAH) A likely first step might be to understand new targets. Evidence to guide clinical decision-making in how to measure success is coming from RCTs, but sometimes it can be difficult to translate this evidence into clinical experience. Professor Vachiéry discussed some of these new targets and investigational therapies, including vasoactive intestinal peptide (VIP)8 and antiproliferative agents.9 As cancer and PAH may share similar pathophysiology of aberrant cell proliferation, growth factor inhibition could play a role in the treatment of PAH, said Professor Vachiéry. But thes

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now